Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

James Chih-Hsin Yang*, Sai-Hong Ignatius Ou, Luigi De Petris, Shirish Gadgeel, Leena Gandhi, Dong-Wan Kim, Fabrice Barlesi, Ramaswamy Govindan, Anne-Marie C. Dingemans, Lucio Crino, Nerve Lena, Sanjay Popat, Jin Seok Ahn, Eric Dansin, Sophie Golding, Walter Bordogna, Bogdana Batas, Peter N. Morcos, Ali Zeaiter, Alice T. Shaw

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1552-1560
Number of pages9
JournalJournal of Thoracic Oncology
Volume12
Issue number10
DOIs
Publication statusPublished - Oct 2017

Keywords

  • Alectinib
  • Non-small cell lung cancer
  • NP28673
  • NP28761
  • Pooled analysis
  • OPEN-LABEL
  • BRAIN METASTASES
  • CRIZOTINIB
  • CHEMOTHERAPY
  • INHIBITORS
  • CERITINIB
  • AF-001JP
  • DISEASE

Cite this